FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
Executive Summary
Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly
You may also be interested in...
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
FDA Soft Sells GMP Quality Overhaul For Generics; Don’t Be ‘Anxious,’ Woodcock Says
‘In some ways our practices have played into the problems we’ve been having,’ CDER director tells GPhA annual meeting as she outlines her plan to ‘radically change’ manufacturing oversight.